Australia - English - Department of Health (Therapeutic Goods Administration)

getinge australia pty ltd - 13735 - sterilization packaging, single-use - sterilization rolls and pouches are intended to provide healthcare workers with an effective method to enclose medical devices intended for sterilization.

Australia - English - Department of Health (Therapeutic Goods Administration)

integrity hospital supplies pty ltd -

United States - English - NLM (National Library of Medicine)

truva seramik kozmetik temizlik pazarlama muteahhitlik nakliyat sanayi ve ticaret ltd sti - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - purpose: antibacterial use: decreases bacteria on the skin

United States - English - NLM (National Library of Medicine)

truva seramik kozmetik temizlik pazarlama muteahhitlik nakliyat sanayi ve ticaret ltd sti - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m), benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - purpose: antibacterial use: decreases bacteria on the skin peel back sealing label. pull top wipe through aperture in pack.close label after use to keep wipes moist.

United States - English - NLM (National Library of Medicine)

truva seramik kozmetik temizlik pazarlama muteahhitlik nakliyat sanayi ve ticaret ltd sti - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m), hydrogen peroxide (unii: bbx060an9v) (hydrogen peroxide - unii:bbx060an9v) - purpose: anti-virus use: decreases virus peel back sealing label. pull top wipe through aperture in pack.close label after use to keep wipes moist.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: powdered cellulose; povidone; macrogol 4000; crospovidone; purified talc; magnesium stearate; microcrystalline cellulose - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. management of 2,8-dihydroxyadenine (2,8-dha) renal stones relate to deficient activity of adenine phosphoribosyl transferase. management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: powdered cellulose; povidone; macrogol 4000; crospovidone; purified talc; magnesium stearate; microcrystalline cellulose - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate and involve hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, glucose-6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. management of 2,8-dihydroxyadenine (2,8-dha) renal stones relate to deficient activity of adenine phosphoribosyl transferase. management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; povidone; croscarmellose sodium; gelatin; indigo carmine; iron oxide red; iron oxide yellow - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; povidone; purified talc; titanium dioxide; croscarmellose sodium; macrogol 400; iron oxide red; iron oxide black; microcrystalline cellulose; magnesium stearate - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; triacetin - tenofovir sandoz in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.,tenofovir sandoz is indicated for the treatment of chronic hepatitis b in adults (see clinical trials).,tenofovir sandoz is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e, active viral replication, persistently elevated serum alt levels or evidence of active inflammation.